NRXS · Neuraxis, INC
$7.15
+0.04 (+0.56%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Neither future cash generated from operating activities, nor management’s contingency plans to mitigate the risk and extend cash resources through the evaluation period, are considered probable. As a result, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern.”View the 10-Q filed Aug 11, 2026
Market Cap
$94.94M
Shares
12.56M
Volume · Oct 5
53.78K
Avg daily vol (3M)
105.99K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.15
Open$7.15
Day$7.07–7.40
52W close$2.31–8.81
Avg vol 30d129K
Short int377K · 3.0% float · 5.4d
Short vol62%
Last earningsAug 11, 2026
DataAug 2023–Oct 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Nov 29, 2026
Est · unconfirmed
· in 8 wks
filed Aug 11, 2026
call held Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$5.32M
Trailing 12 months
Net income (TTM)
−$7.68M
Trailing 12 months
Revenue growth YoY
+115.7%
Year over year
Operating margin
-144.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+42.2%
Year over year · more shares
Price change (1Y)
+122.9%
Trailing year
Short interest
3.0%
Latest settlement · 5.4 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+12%
above
Price vs 50-day avg
+9%
above
RSI (14)
55
neutral
MACD trend
Negative
52-week position
74%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+20%
trailing
6-month return
0%
trailing
YTD return
+57%
this year
Relative strength
−12%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
+23% holders QoQ · +9 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.00% of float · ▲ +51.7% MoM · 5.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
32 holders — near 3-yr high, broad support
Squeeze score
67
elevated · 0–100
Fundamentals
Revenue growth
+33%
Y/Y
Gross margin
84%
contracting
EPS growth
+22%
Y/Y
Free cash flow
$-6.5M
Balance sheet
$25.4K
net cash
Quant / Vol
risk profile
Volatility
76%
annualized · 1-yr
Max drawdown
−40%
past year
ATR
7.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+12%
Bullish
Price vs 50-day avg
+9%
Bullish
RSI (14)
55
Neutral
MACD trend
Negative
Bearish
52-week position
74%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
+23% holders QoQ · +9 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.00% of float · ▲ +51.7% MoM · 5.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
32 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $7 · 74%
Range high $9
vs 200-day avg +12%
vs 50-day avg +9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NRXS
this stock
Neuraxis, INC
|
$94.94M | +57.5% | +32.9% | — | 3.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NRXS | -3.4% | +20.0% | -0.4% | -3.0% | +57.5% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -4.6% | +19.4% | -12.0% | -4.6% | +43.9% |